Skip to main content

Leica Biosystems Announces Full Ownership of Jung Feintechnik

Leica Biosystems Announces Full Ownership of Jung Feintechnik

RICHMOND, IL, December 20, 2013 – Leica Biosystems today announced that it has increased its ownership of Jung Feintechnik from 50% to 100%.

Jung Feintechnik is based in Eisfeld, Germany. It is a developer and manufacturer of high quality sectioning products for the Histology process, most recently collaborating on Leica Biosystems’ DB80Premium Microtome Blade.

“The acquisition is important for us as it allows Leica Biosystems to continue developing high quality, innovative sectioning products for the global histopathology market” said John Kody, General Manager, Leica Biosystems Core Histology Consumables.

Leica Biosystems has been working with Jung Feintechnik since 1999 and has invested heavily in quality within the manufacturing area.

According to Leica Biosystems’ President, Dr. Matthias Weber, “We believe the quality of the products developed and manufactured in the Eisfeld facility provide real clinical advantage to our customers.”

Financial details of the acquisition have not been made available.

About Leica Biosystems

Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Our easy‐to‐use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in seven countries, sales and service organizations in 19
countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at


Media Contact(s): Tim Lyons, Director, Marketing Communications,,